Option chain shows key data for Valneva's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Valneva.

Valneva (NASDAQ:VALN) Stock, Option Chain

Valneva

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Novavax,Vaccine,For,Prevention,Of,Coronavirus,,Covid-19,,Sars-cov-2,In,Doctors

Biotech

Large Cap

News

Eurozone

Health Care

Movers

Trading Ideas

General

BNTX

MRNA

VALN

Vaccine stocks react to Robert F. Kennedy Jr.&#39;s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts.

European And US Vaccine Stocks Are Under Pressure - Here&#39;s WHy

Palo Alto Networks

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

AFRM

EBAY

MBLY

PANW

RACE

Palo Alto Networks To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday

Adobe

ADBE

AVIR

GOGO

SLQT

SMWB

Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Valneva SE

Management

JJSF

J & J Snack Foods Appoints Shawn Munsell As CFO

Contracts

SIDU

Sidus Space And Reflex Aerospace Partner To Advance Dual-Use Satellite Development, Strengthening U.S. And European Space Infrastructure With Collaborative Launch Planned For 2025; No Financial Terms Disclosed

BLEU

Trading Halt: Halted at 8:35:56 a.m. ET - Trading Halt: Halt News Pending

BLEUR

BLEUU

BLEUW

Wells Fargo analyst Michael Turrin maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Equal-Weight and raises the price target from $125 to $150.

SNOW

Wells Fargo Maintains Equal-Weight on Snowflake, Raises Price Target to $150

WIIM

VSTS

Vertis shares are trading lower after the company issued FY25 sales guidance below estimates.

On Thursday, Temu parent&nbsp;PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)&nbsp;reported&nbsp;fiscal third-quarter 2024&nbsp;revenue growth of 44% year-on-year to $14.16 billion (68.84 billion Chinese yuan), missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42107689/pdd-holdings-announces-third-quarter-2024-unaudited-financial-results" rel="noreferrer noopener">analyst consensus estimate of $14.47 billion</a>.
The Chinese online retailer's adjusted earnings per ADS of $2.65 (18.59 Chinese yuan) increased from 11.61 Chinese yuan Y/Y, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $2.82</a>.&nbsp;The stock plunged after the print.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42032495/alibaba-eyes-5-billion-bond-sale-to-fund-debt-payoff-and-stock-buybacks" rel="noreferrer noopener">Alibaba Eyes Raising $5 Billion Via Bond Sale to Fund Debt Payoff and Stock Buybacks</a>
Revenues from online marketing services and others rose 24% Y/Y to $7.03 billion. Revenues from transaction services jumped 72% Y/Y to $7.13 billion.
Adjusted operating profit grew by 48% Y/Y to $3.81 billion.
PDD Holdings held $44.0 billion in cash and equivalents as&nbsp;of September 30, 2024. The company generated $3.92 billion in operating cash flow.
Over the past quarter, PDD Holdings focused on advancing the high-quality development of its platforms, prioritizing consistent and strategic investments in its ecosystem for long-term impact.
Co-CEO Jiazhen Zhao said that during the third quarter, the company increased investments in its platform ecosystem by introducing merchant support initiatives and enhancing trust and safety measures.
This approach encouraged high-quality merchants to elevate their product and service offerings, creating a positive cycle of growth and improvement.
VP of Finance Jun Liu said that topline growth moderated quarter-on-quarter due to intensified competition and external challenges.
PDD Holdings stock plunged over 20% year-to-date.
Price Action: At the last check on Thursday, PDD stock traded lower by 11.20% to $103.50 premarket.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41948430/whats-going-on-with-us-listed-chinese-stocks-alibaba-jd-nio-li-xpeng-on-wednesday" target="_blank" rel="noreferrer noopener">Alibaba, JD.com Report Strong Singles' Day Sales as U.S.-China Tensions Weigh on Stocks</a></li>
</ul>
Photo via Shutterstock

Earnings

Emerging Markets

Tech

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Temu Parent PDD Stock Tumbles After Q3 Profit Miss, Company Cites Intensified Competition and External Challenges

SRAD

Sportradar Signs Multiyear Agreement With MLB To Provide Sports Performance Analysis Of Prospects Through Its Synergy Coaching And Scouting Solution

CDTX

Cidara Therapeutics Secures $105M In Private Placement; Closing Expected November 25, 2024

WAVE

Eco Wave Power Global Q3 EPS $(0.012) Down From $(0.004) YoY

XBIO

Xenetic Biosciences Presents Preclinical Data On DNase I Co-Administration With CAR T Cells, Highlighting Potential To Enhance Therapeutic Responses In Melanoma Lung Metastasis Model

DRIO

Dario Signs Four Contracts With Self-Insured Employers That Are Expected To Go Live In Q1 Of 2025

WALD

Waldencast shares are trading higher after the company reported a year-over-year increase in Q3 sales results.

Wells Fargo analyst Aaron Rakers maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Overweight and raises the price target from $165 to $185.

NVDA

Wells Fargo Maintains Overweight on NVIDIA, Raises Price Target to $185

Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Outperform and raises the price target from $675 to $706.

ARGX

Evercore ISI Group Maintains Outperform on argenx, Raises Price Target to $706

JAZZ

ZYME

Jazz Pharmaceuticals and Zymeworks shares are trading higher after announcing their Zihera collaboration secured FDA approval to treat HER2-positive biliary tract cancer in adults.

CIMG Secures Distribution Agreements To Sell Maca Noni Beverage In 550 Lawson Stores And Targets Expansion To 25,000 uSmile PetroChina Locations, 400 Guangdong Petroleum Stores, And 129 Chengdu Energy Gas Stations Over Three Years

Wells Fargo analyst Andrew Nowinski maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Overweight and raises the price target from $416 to $450.

Wells Fargo Maintains Overweight on Palo Alto Networks, Raises Price Target to $450

Warning: VALN is at high risk of performing badly

Valneva reports nine-month results

Valneva (VALN) has released an update. Valneva SE has reported €116.6 million in total revenues for the first nine months of 2024, with a notable t...

Valneva Reports Profitable Quarter Amid Vaccine Launches

Kepler Capital analyst Justine Telliez maintained a Buy rating on Valneva (0OB3 – Research Report) on November 7 and set a price target of €8.10. T...

Kepler Capital  Remains a Buy on Valneva (0OB3)

Valneva SE (VALN) Q3 2024 Earnings Call Transcript

Valneva (VALN) has released an update. Valneva is set to engage with institutional investors at major U.S. and European healthcare conferences, whe...

Valneva Engages Investors with Promising Vaccine Developments

In a report released on November 14, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a price ...

INRLF

Press Releases

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Financing

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

Valneva to Host Investor Day in New York  on Thursday, October 10, 2024 at 10:00 AM ET

Valneva Hosts Investor Day in New York City

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Comments

Valneva

Valneva (VALN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga